ESSB 5403
SignedSenate
Cannabis industry agreements
Supporting a sustainable cannabis industry. (REVISED FOR ENGROSSED: Limiting financial interest agreements for licensed cannabis retailers.)
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill allows licensed cannabis producers and processors in Washington to sell cannabis flower directly to consumers, under strict conditions, to help small and independent producers stay in business amid price pressures from federal restrictions. It explicitly preserves the role of retailers while adding a new, limited sales channel. The 37% excise tax applies to these new sales, and the bill updates licensing fees and reporting requirements.
- Allows licensed cannabis producers and processors to sell cannabis flower directly to consumers, but only if the flower is produced or processed at their own licensed facility and they comply with existing purchase limits (RCW 69.50.360).
- Prohibits producers and processors from replacing or displacing retailers—this new sales path is intended as a limited supplement to the existing retail system.
- Requires the Washington State Liquor and Cannabis Board to adopt rules for security and operations for these direct-to-consumer sales, but those rules cannot be stricter than those for retailers.
- Amends license fee amounts for producers and processors to $250 application fee and $1,381 annual fee (unchanged from prior law, but corrected in text from older dollar amounts).
- Clarifies that the 37% cannabis excise tax applies to direct-to-consumer flower sales by producers and processors, and requires the tax to be itemized on receipts.
- Extends the medical cannabis tax exemption (for qualifying patients) to sales made directly by producers/processors, not just retailers, and requires separate reporting of exempt sales.
Who is affected
- Cannabis producers and processors — Cannabis producers and processors licensed under state law may now sell cannabis flower directly to consumers, under specific conditions, to help improve their financial sustainability.
- Cannabis consumers — Consumers gain access to cannabis flower purchased directly from producers or processors (not just retailers), potentially increasing product variety and supporting local producers.
- Cannabis retailers — Cannabis retailers continue to operate as before, but now face new competition from producers and processors selling directly to consumers—though the bill explicitly states this new pathway is not meant to replace retailers.
- State and local governments — The state government collects excise taxes from these new direct-to-consumer sales, which go into the dedicated cannabis account for health care, education, and human services funding.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (5)
Direct-to-consumer sales provide a new revenue stream for small and independent producers and processors—especially those struggling under federal restrictions that limit out-of-state sales and drive down wholesale prices—potentially preventing business closures and preserving local jobs in rural and minority-owned cannabis businesses.
Business & EmploymentPeopleRef: Sec. 1(3), Sec. 2, Sec. 4(2)(a)By allowing producers and processors to bypass wholesale intermediaries and sell directly, the bill may reduce markups and increase price transparency—potentially lowering costs for consumers and increasing affordability, especially for low-income and medical patients.
FinancialPeopleRef: Sec. 1(2), Sec. 2, Sec. 4(3)(c)Extending the 37% excise tax to direct sales ensures broader tax base coverage and could increase state and local revenue—funds that support health care, education, and human services, especially in communities disproportionately impacted by past cannabis prohibition.
Local GovernmentPeopleRef: Sec. 1(1), Sec. 4(3)Extending the medical cannabis tax exemption to direct sales by producers/processors improves access for qualifying patients who may not shop at traditional retailers—especially important in rural or underserved areas with limited retail access.
HealthcareLean peopleRef: Sec. 2(3), Sec. 4(2)(a), Sec. 4(2)(b)The bill’s explicit intent to preserve retailers while adding a limited direct channel may encourage vertical integration in a fragmented industry—potentially stabilizing supply chains and supporting long-term industry sustainability, though this may disproportionately benefit larger players with capital to expand operations.
Business & EmploymentLean peopleRef: Sec. 1(3), Sec. 2
Potential Concerns (5)
Allowing producers and processors to sell directly to consumers may increase the risk of noncompliance with purchase limits (e.g., 3-gram limit for flower under RCW 69.50.360), especially if licensing and monitoring infrastructure is not scaled to support this new channel—potentially undermining consumption limits intended to protect public health and safety.
Public SafetyLean peopleRef: Sec. 2(1)(b), Sec. 2(2)(b), RCW 69.50.360While the bill preserves retailers, it introduces a new competitive channel for producers and processors—potentially diverting foot traffic and sales from independent retailers, especially those in rural or low-income areas that lack vertical integration and cannot match direct pricing from large producers.
Business & EmploymentLean peopleRef: Sec. 2(3) and Sec. 4(3)(c)By eliminating the board’s requirement to report tax impacts to the legislature after January 1, 2025, the bill reduces legislative oversight of cannabis tax revenue flows—potentially weakening accountability for how funds are allocated across health care, education, and human services, which could indirectly affect service quality for everyday Washingtonians.
Local GovernmentRef: Sec. 4(6)(c)The requirement that only cannabis flower produced or processed *at the licensee’s own facility* may be sold directly limits flexibility for small operators who rely on contract manufacturing or sourcing from other licensed facilities—potentially excluding micro-businesses and new entrants who lack full vertical integration.
Business & EmploymentRef: Sec. 2(1)(a), Sec. 2(2)(a)Extending the medical cannabis tax exemption to direct sales by producers/processors is administratively neutral—while it preserves access for qualifying patients, it does not expand eligibility or coverage, and the exemption applies only to a subset of products and patients already covered under existing law.
HealthcareRef: Sec. 4(2)(a), Sec. 4(2)(b)
Who Is Most Affected
Small and independent producers and processors—especially those without retail licenses—may benefit significantly from new sales channels, improving cash flow and reducing reliance on volatile wholesale markets. However, those without capital to scale operations or meet security/operational requirements may still be excluded.
Large vertically integrated producers may gain disproportionate advantage by leveraging scale to undercut smaller retailers, especially in high-demand markets. The policy may accelerate consolidation despite its stated intent to support small producers.
Retailers—especially independent, single-location shops—may face competitive pressure as producers sell directly, potentially reducing foot traffic and margins. However, those with strong branding or unique product lines may adapt.
Low-income and medical cannabis patients may benefit from increased affordability and access, especially if direct sales reduce markups and expand geographic availability. However, the impact is limited by purchase caps and lack of delivery provisions.
State and local governments benefit from expanded tax base and dedicated revenue streams for health and human services. However, reduced legislative reporting after 2025 may weaken oversight of fund allocation and equity outcomes.